Skip to main content
. 2009 Oct 7;101(19):1308–1324. doi: 10.1093/jnci/djp280

Figure 3.

Figure 3

Progression-free interval by response to panitumumab in a subgroup of patients with metastatic colorectal cancer whose tumors carry wild-type KRAS. Data are from a phase III study (27,61).